



In Vitro Development of Targeted Drugs and Nanoparticles

Guest Editor:

Dr. Vilma Petrikaitė

1. Institute of Biotechnology,
Vilnius University, V. A. Graičiūno
8, 02241 Vilnius, Lithuania
2. Institute of Cardiology,
Lithuanian University of Health
Sciences, A. Mickevičiaus g. 9,
LT44307 Kaunas, Lithuania

Deadline for manuscript
submissions:

closed (30 September 2022)

Message from the Guest Editor

During the last decades, there has been an increasing focus on the design and development of targeted drugs, including nanotherapeutics. Mostly nanosystems and targeted drugs are being developed for cancer therapy and diagnostics in order to reduce possible toxic effects, improve bioavailability and increase clinical efficiency. However, nanomedicine still receives criticism mainly due to the lack of high affinity with respect to targeted tissue. Thus, more efficient strategies for targeting desirable tissues and combating resistance to therapy are needed. Currently, many actively targeting molecules are being investigated in various models in vitro and in vivo, providing new hope for more specific personalized therapy for many diseases.

This Special Issue seeks high quality studies focusing on targeted therapy and nanotechnology applied in personalized therapy areas. Topics include but are not limited to the following:

- Design of new molecules for targeted therapy and diagnostics;
- Development of targeted peptides/antibodies;
- Development of nanocarriers for personalized and precision medicine;
- Development of new nanomaterials for personalized therapy.





an Open Access Journal by MDPI

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and
Molecular Medicine, Faculty of
Health and Medical Sciences,
University of Copenhagen,
Blegdamsvej 3C, DK-2200
Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer
Science, Virginia Commonwealth
University, Richmond, VA 23284,
USA

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Biochemistry*)

Contact Us

Biomolecules Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomolecules
biomolecules@mdpi.com
[X@Biomol_MDPI](https://twitter.com/Biomol_MDPI)